Market capitalization | $172.27m |
Enterprise Value | $118.60m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 3.22 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-22.38m |
Free Cash Flow (TTM) Free Cash Flow | $-19.52m |
Cash position | $54.06m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
3 Analysts have issued a DiaMedica Therapeutics Inc. forecast:
3 Analysts have issued a DiaMedica Therapeutics Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.03 -0.03 |
50%
50%
|
|
EBITDA | -22 -22 |
29%
29%
|
EBIT (Operating Income) EBIT | -22 -22 |
29%
29%
|
Net Profit | -20 -20 |
20%
20%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
DiaMedica Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It offers DM199 product which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.
Head office | Canada |
CEO | Rick Pauls |
Employees | 19 |
Founded | 2000 |
Website | www.diamedica.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.